GCM
LUCD icon

Graham Capital Management’s Lucid Diagnostics LUCD Stock Holding History

Graham Capital Management’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-29,950
Closed -$34.4K – 1475
2025
Q2 		$34.4K Buy
+29,950
New +$38.7K ﹤0.01% 1252

Other funds holding LUCD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCM
Masters Capital Management Atlanta, Georgia $3.03B AUM 57.21% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
GCM
Ghisallo Capital Management Boston, Massachusetts $3.63B AUM 30.51% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

Graham Capital Management's LUCD Position: Q3 2025 in Review

Graham Capital Management sold out of Lucid Diagnostics (LUCD) in Q3 2025, closing a stake of 29,950 shares — an estimated $34.4K sold.

Graham Capital Management first reported a position in LUCD in Q2 2025 and held it in 1 quarter. The position peaked at $34.4K in Q2 2025. 86 funds tracked by Wall St. Rank hold LUCD as of Q3 2025.

  • Graham Capital Management reported no remaining Lucid Diagnostics position as of Q3 2025 after selling out during the quarter.
  • Graham Capital Management sold 29,950 Lucid Diagnostics shares in Q3 2025, an estimated $34.4K.
  • Graham Capital Management first reported a position in Lucid Diagnostics in Q2 2025 and held it in 1 quarter.
  • Graham Capital Management's Lucid Diagnostics position peaked at $34.4K in Q2 2025.
  • 86 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q3 2025.

Based on Graham Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.